GLP-1 Drugs Lower Breast Cancer Risk by 30%

• A brand new examine discovered that females utilizing GLP-1 medication had a few 30% decrease danger of creating breast most cancers.
• The impact could also be associated to the metabolic enhancements related to this class of medicines.
• Extra analysis is required earlier than GLP-1 medication will be beneficial for breast most cancers prevention.
• Consultants say that common screening and a wholesome life-style stay necessary preventive measures.

A brand new examine from the College of Pennsylvania has discovered that girls who take GLP-1 drugs are about 30% much less prone to develop breast most cancers.

Semaglutide, the energetic ingredient in GLP-1 medication like Ozempic and Wegovy, mimics a hormone referred to as glucagon-like peptide-1, which helps regulate blood sugar and urge for food. GLP-1 medications had been initially developed to deal with type 2 diabetes, however are additionally broadly prescribed for weight reduction.

The brand new analysis raises hope that GLP-1 medication might function a method for breast cancer prevention, particularly amongst higher-risk females with obese and obesity.

The findings come at a second when scientists are exploring using GLP-1 medication to deal with different circumstances past kind 2 diabetes and weight problems, similar to sleep apnea and addiction.

The analysis group performed a retrospective cohort examine utilizing digital well being data from the College of Pennsylvania Well being System, which incorporates each tutorial and neighborhood medical websites throughout Pennsylvania and New Jersey.

Throughout this course of, they recognized 217,624 females who underwent breast imaging between January 1, 2022, and June 30, 2025. The examine centered on 111,646 females ages 45 to 80 who had been obese or overweight (BMI ≥ 25) and had documented breast imaging outcomes.

Amongst these contributors, 15,264 (13.7%) had been prescribed GLP-1 drugs previous to their imaging examination, whereas 96,382 (86.3%) had no report of GLP-1 use.

To make sure a good comparability and cut back bias, the researchers carried out a one-to-one case-control matching.

Every girl taking GLP-1 medication was matched with a girl not taking the medication, primarily based on elements similar to age, race, ethnicity, BMI, breast density, and diabetes standing. This matching course of helped management for variables that might independently affect breast most cancers danger, unbiased of GLP-1 use.

The first end result measured was the prognosis of recent breast most cancers in the course of the examine interval.

Statistical modeling was used to investigate the affiliation between GLP-1 publicity and breast most cancers incidence.

The researchers’ evaluation discovered a big affiliation between GLP-1 use and decreased breast most cancers danger.

Females taking GLP-1 drugs had about 35% decrease odds of creating breast most cancers in comparison with those that didn’t use these medication within the full cohort.

Within the matched cohort, which managed for potential confounding elements, GLP-1 use was related to a 30.5% discount in breast most cancers incidence.

Particularly, among the many 15,264 females on GLP-1 medication, 1.62% had been recognized with breast most cancers in the course of the examine, in comparison with 2.47% of the 96,382 females who didn’t use GLP-1 drugs. This translated into an absolute danger discount of about 0.69%.

The protecting impact of GLP-1 drugs was constant throughout racial teams, together with Black and white females, and was unbiased of diabetes standing, age, BMI, and breast density.

The researchers imagine a number of mechanisms might clarify these findings.

GLP-1 medication not solely promote weight loss, which is thought to scale back breast most cancers danger, however in addition they cut back systemic inflammation, a recognized contributor to most cancers improvement.

Laboratory research have additionally proven that GLP-1 agonists might immediately inhibit most cancers cell development and alter metabolic pathways important to tumor survival.

Whereas the examine was observational and can’t show causation, its giant pattern measurement and rigorous matching lend weight to the outcomes.

Nevertheless, the researchers emphasised that potential scientific trials are essential to definitively decide whether or not GLP-1 drugs can forestall breast most cancers and to know the underlying organic mechanisms.

This examine opens the door to exploring GLP-1 medication as a probably safer different to current breast most cancers preventive drugs, which frequently have vital uncomfortable side effects.

Given the widespread use of GLP-1 drugs for weight management and diabetes, the findings might have vital public well being implications.

Monique Gary, DO, a breast surgical oncologist at St. Luke’s College Well being Community who wasn’t a part of the analysis group however did attend the convention, stated that GLP-1 might be exerting this impact as a result of a number of elements affect breast most cancers danger.

“GLP-1s could also be influencing breast most cancers danger not directly by bettering a number of the metabolic elements we all know matter, together with weight, insulin resistance, irritation, and the hormonal atmosphere,” she advised Healthline.

Gary additional famous that adipose tissue is metabolically energetic and may have an effect on estrogen manufacturing and inflammatory signaling, each of that are concerned in breast most cancers biology.

On the similar time, she stated it’s necessary to notice that what was seen was merely a statistical affiliation.

“It doesn’t show that GLP-1s forestall breast most cancers, and these drugs aren’t FDA-approved for most cancers prevention or most cancers therapy,” Gary defined.

However, these findings are necessary, she stated, as a result of they reinforce that breast most cancers prevention entails “the complete danger image” reasonably than only one issue.

“GLP-1s might turn into half of a bigger prevention dialog for some sufferers sooner or later,” stated Gary, “however they aren’t a substitute for screening, danger evaluation, or individualized medical steering.”

Whereas GLP-1s might play a future function in breast most cancers prevention, Mia Kazanjian, MD, a board licensed radiologist and director of Ladies’s Imaging at Norwalk Radiology Consultants, stated there are a number of steps ladies can take proper now to assist cut back their danger. Kazanjian wasn’t concerned within the examine.

Breast cancer screening is a vital a part of this course of, she advised Healthline. Females ought to usually get annual mammograms, together with an ultrasound if they’ve dense breast tissue.

“Societies advocate beginning at age 40 if common danger, although I like to recommend a baseline at 35 yo as I follow in CT, which has the very best charge of early onset breast most cancers within the U.S.,” stated Kazanjian.

She added that females might want to take into account a breast cancer risk assessment utilizing the Tyrer-Cuzick Mannequin by the age of 25, and even sooner in the event that they’re at excessive danger.

The worth of breast most cancers danger evaluation made headlines in 2024 when actor Olivia Munn shared that it led to her early breast cancer prognosis.

Moreover, Kazanjian prompt embracing a wholesome life-style as part of your prevention plan.

“About half-hour of average exercise a day is good,” stated Kazanjian. “This may be divided into smaller chunks of time for busy individuals.”

Kazanjian additionally prompt following a plant-based weight-reduction plan with lean protein. “Keep away from ultra-processed meals,” she added.

Lastly, Kazanjian stated it’s necessary to keep away from cigarettes and alcohol. “Any quantity [of alcohol] will increase danger of breast most cancers,” she warned.